Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465792 | 1.00 | TPMT (0.51) | TPMTPKMLMNAHTTPOLB | |
| Potassium Ion SCHEMBL2681690 | 0.98 | TPMT (0.50) | TPMTPKMLMNAHTTPOLB | |
| SCHEMBL2681686 | 0.98 | TPMT (0.50) | TPMTPKMLMNAHTTPOLB | |
| SCHEMBL3698713 | 0.97 | PKM (0.52) | TPMTPKMLMNAHTTPOLB | |
| SCHEMBL16945800 | 0.94 | PKM (0.55) | TPMTPKMLMNAHTTPOLB | |
| SCHEMBL28708249 | 0.93 | POLB (0.46) | TPMTPKMLMNAHTTPOLB | |
| SCHEMBL31549975 | 0.88 | PKM (0.59) | PKMLMNAHTTPOLBCYP3A4 | |
| SCHEMBL375897 | 0.88 | PKM (0.59) | PKMLMNAHTTPOLBCYP3A4 | |
| Methyl Alcohol SCHEMBL27781670 | 0.87 | PKM (0.58) | PKMLMNAHTTPOLBCYP3A4 | |
| Potassium Ion SCHEMBL2681688 | 0.86 | LMNA (0.47) | TPMTPKMLMNAHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-110590683-A | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118852118-A | Compounds that inhibit tyrosine kinase activity and pharmaceutical compositions comprising the same | 德州大学系统董事会 | 2024-10-29 | — | — | CN | disclosed |
| CN-114026083-B | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2024-07-09 | — | — | CN | disclosed |
| CN-116444447-B | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-116568689-A | Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| WO-2023287730-A1 | TRICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-110590683-B | Preparation method of intermediate of targeting drug AZD3759 | 山东四环药业股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022170917-A1 | POLYCYCLIC PYRIMIDINE DERIVATIVE AS SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2003-03-06 | — | — | US | disclosed |
| EP-0875506-B1 | Quinoline and quinazoline compounds useful in therapy | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014772-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | RET, CYP11B1, CYP11B2 | TPMT 3074/4885PKM 108/4885LMNA 1003/4885 |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, BPHL | TPMT 1566/4885PKM 1800/4885LMNA 378/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | TPMT 2786/4885PKM 3276/4885LMNA 4148/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | TPMT 1375/4885PKM 1875/4885LMNA 411/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | TPMT 4333/4885PKM 3959/4885LMNA 3951/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | TPMT 2563/4885PKM 1864/4885LMNA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.